Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease
T Müller - Expert opinion on drug metabolism & toxicology, 2020 - Taylor & Francis
Introduction: Parkinson's disease is a chronic, neurodegenerative disease entity with
heterogeneous features and course. Levodopa is the most efficacious dopamine substituting …
heterogeneous features and course. Levodopa is the most efficacious dopamine substituting …
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease
Y Goshima, D Masukawa, Y Kasahara… - Frontiers in …, 2019 - frontiersin.org
l-3, 4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for
Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that …
Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that …
Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia
M Asghar, A Odeh, AJ Fattahi, AE Henriksson… - Scientific Reports, 2022 - nature.com
Progressive age is the single major risk factor for neurodegenerative diseases. Cellular
aging markers during Parkinson's disease (PD) have been implicated in previous studies …
aging markers during Parkinson's disease (PD) have been implicated in previous studies …
Reactive astrocytes targeting with oral vitamin A: Efficient neuronal regeneration for Parkinson's disease treatment and reversal of associated liver fibrosis
NS El‐Mezayen, MAM Attia, MY Shafik… - CNS Neuroscience …, 2023 - Wiley Online Library
Introduction A recent approach to cure neurodegenerative diseases is to reprogram
fibroblasts into functioning neurons using multiple exogenous transcription factors (TFs) and …
fibroblasts into functioning neurons using multiple exogenous transcription factors (TFs) and …
Современное состояние проблемы нейропластичности в психиатрии и неврологии
ИВ Галанин, АГ Нарышкин, АЛ Горелик… - … им. ИИ Мечникова, 2015 - cyberleninka.ru
В обзоре описаны морфологические, биохимические и нейровизуализационные
изменения, возникающие как в процессе болезни, так и при последующем лечении …
изменения, возникающие как в процессе болезни, так и при последующем лечении …
[PDF][PDF] A study of the non-motor symptoms in early Parkinson's disease with olfactory deficits.
L Wu, N Mu, F Yang, J Zang… - European Review for …, 2016 - europeanreview.org
OBJECTIVE: The aim of this study is to determine characteristics of non-motor symptoms
(NMS) in early Parkinson's disease (PD) with olfactory deficits and to analyze the feasibility …
(NMS) in early Parkinson's disease (PD) with olfactory deficits and to analyze the feasibility …
帕金森病的非运动症状及研究进展
黄星会， 霍丽涛， 吴庆文， 梁伟 - 中国康复理论与实践, 2013 - cqvip.com
帕金森病的非运动症状及研究进展-[维普官方网站]-www.cqvip.com-维普网 我的维普 购物车
充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术 …
充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术 …
The role of β-adrenergic blockers in Parkinson's disease: possible genetic and cell-signaling mechanisms
K Lương, LTH Nguyễn - American Journal of Alzheimer's …, 2013 - journals.sagepub.com
Genetic studies have identified numerous factors linking β-adrenergic blockade to
Parkinson's disease (PD), including human leukocyte antigen genes, the renin–angiotensin …
Parkinson's disease (PD), including human leukocyte antigen genes, the renin–angiotensin …
美多巴单用及联合普拉克索治疗帕金森病的疗效和安全性比较
姜立刚， 李海平， 李威 - 中国老年学杂志, 2016 - cqvip.com
目的探讨美多巴单用及联合普拉克索治疗帕金森病(PD) 的疗效和安全性. 方法选取100
例该院帕金森病专病门诊及住院PD 患者, 随机分为观察组和对照组各50 例. 对照组给予美多巴 …
例该院帕金森病专病门诊及住院PD 患者, 随机分为观察组和对照组各50 例. 对照组给予美多巴 …
Cdk5 及p35 在NGF 撤退诱导的已分化PC12 细胞凋亡中的作用研究
沈晗， 吴少波， 张百芳， 彭芳芳， 武栋成 - 暨南大学学报: 自然科学与医学版, 2012 - cqvip.com
目的: 探讨Cdk5 及p35 在神经生长因子(NGF) 撤退诱导的PC12 细胞凋亡中的作用机制. 方法:
建立NGF 撤退诱导的已分化PC12 细胞凋亡模型, Western blotting 检测Cdk5 及p35 …
建立NGF 撤退诱导的已分化PC12 细胞凋亡模型, Western blotting 检测Cdk5 及p35 …